Research area: Diabetes, prediabetes and cardiovascular complications. Foucs on undiscovered diabetes, AMI and heart failure complications, cardiovascular preventive treatment and registry research.
Adjunct Professor of Cardiology at the Department of Medicine, Solna from October 1, 2019. Primary position: Senior physician at Capio S:t Göran’s Hospital.
Anna Norhammar is a cardiologist and clinical physiologist who researches cardiovascular complications of diabetes and prediabetes. Her finding that people with diabetes, due to a lack of application of evidence-based treatment, have twice the risk of mortality after a myocardial infarction led to improved treatment in Sweden and globally – and to significantly higher survival rates. Her research has further shown that patients with diabetes continue to have an increased risk of heart failure and a worse prognosis than other patients with heart failure.
Other findings from Norhammar’s research include that new heart-protecting diabetes drugs are indeed effective outside clinical studies (in real-life) but too rarely used, and that about a third of myocardial infarction patients without known diabetes, have undetected diabetes, and another third have precursors of the disease. Norhammar is now engaged in planning for a randomised study on whether the drug Metformin can improve the cardiovascular prognosis for patients with prediabetes.
Text: From Cell to Society, 2020